News
| Feb 10 | $BMY gave up on it. Any day by h8lesstr8dr |
| Feb 10 | Final Glance: Pharmaceuticals companies |
| Feb 10 | Big Pharma: 3 To Avoid, 1 To Buy |
| Feb 10 | Midday Glance: Pharmaceuticals companies |
| Feb 10 | Early Glance: Pharmaceuticals companies |
| Feb 10 | Sanofi Beats Earnings Estimates |
| Feb 10 | Sanofi Beats Earnings Estimates - Analyst Blog Zacks |
| Feb 10 | We Need A New Religion |
| Feb 10 | DIARY-U.S. MEETINGS/WEEK AHEAD |
| Feb 10 | The Truly Staggering Cost Of Inventing New Drugs |
| Feb 08 | Recap yestarday short list: $aep $bmy $duk $noc $xlu $nbr $kss $bk #trading #spy #finance $SPY http://chart.ly/3xbo8qm by dariabarbu75 |
| Feb 07 | $BMY set stop @ 31.8 by aceTR8DER |
| Feb 07 | watchlist for today: $aep $bmy $duk $noc $xlu $nbr $kss $bk #finance #trading #nyse $SPY http://chart.ly/ve6fe8v by dariabarbu75 |
| Feb 07 | Catch the next leg up in $ONTY now. $dndn $idix $bmy by Shorty |
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Major
Bristol-Myers Squibb Company (BMS), incorporated in August 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. On October 12, 2010, the Company acquired ZymoGenetics, Inc. (ZymoGenetics). In September 2011, the Company acquired Amira Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Bristol-Myers Squibb Company is up N/A over the last year vs S&P 500 Total Return up N/A, Pfizer up N/A, and Merck up N/A.
- BMY Total Returns
- ^SPXTR Total Returns
- PFE Total Returns
- MRK Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these BMY related companies
Pro Strategies Featuring BMY
Did Bristol-Myers Squibb Company make it into our Pro Portfolio Strategies?
BMY Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other BMY Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Quote.com
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMY | 31.90 | -0.09 | -0.28% | 54.06B |
| CVS | 43.18 | 0.18 | 0.42% | 56.20B |
| MU | 7.91 | -0.26 | -3.12% | 7.81B |
| VZ | 37.69 | -0.23 | -0.61% | 106.70B |
| HVT | 12.04 | -0.27 | -2.19% | 264.28M |
| CETV | 8.67 | -0.33 | -3.67% | 558.26M |
| HPQ | 28.70 | -0.41 | -1.41% | 57.03B |
| NLY | 16.54 | 0.06 | 0.36% | 16.03B |
| DTV | 45.51 | -0.05 | -0.11% | 33.60B |
| HON | 59.33 | -0.56 | -0.94% | 45.89B |
